Optimizing drug therapy for older adults: shifting away from problematic polypharmacy

被引:0
|
作者
Daunt, Ruth [1 ,2 ]
Curtin, Denis [1 ,2 ]
O'Mahony, Denis [1 ,2 ]
机构
[1] Univ Coll Cork, Sch Med, Dept Med Geriatr, Cork T12 DC4A, Ireland
[2] Cork Univ Hosp, Dept Geriatr Med, Cork, Ireland
关键词
Artificial intelligence; geriatric medicine; medication-related harm; multimorbidity; problematic polypharmacy; deprescribing; RIGHT TREATMENT CRITERIA; ARTIFICIAL-INTELLIGENCE; SCREENING TOOL; PEOPLE; PREVALENCE; HEALTH; MULTIMORBIDITY; INTERVENTION; OUTCOMES; IMPACT;
D O I
10.1080/14656566.2024.2374048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionThe accelerated discovery and production of pharmaceutical products has resulted in many positive outcomes. However, this progress has also contributed to problematic polypharmacy, one of the rapidly growing threats to public health in this century. Problematic polypharmacy results in adverse patient outcomes and imposes increased strain and financial burden on healthcare systems.Areas coveredA review was conducted on the current body of evidence concerning factors contributing to and consequences of problematic polypharmacy. Recent trials investigating interventions that target polypharmacy and emerging solutions, including incorporation of artificial intelligence, are also examined in this article.Expert opinionTo shift away from problematic polypharmacy, a multifaceted interdisciplinary approach is necessary. Any potentially successful strategy must be adapted to suit various healthcare settings and must utilize all available resources, including artificial intelligence.
引用
收藏
页码:1199 / 1208
页数:10
相关论文
共 50 条
  • [1] Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease
    Lozano-Lozano, Rodrigo
    Vega-Morales, David
    Sifuentes-Martinez, Macarena del Rosario
    Ornelas-Balcazar, Denisse
    REUMATOLOGIA CLINICA, 2024, 20 (05): : 249 - 253
  • [2] Antineoplastic Therapy Side Effects and Polypharmacy in Older Adults With Cancer
    Stout, Nicole L.
    Wagner, Susan Sabo
    TOPICS IN GERIATRIC REHABILITATION, 2019, 35 (01) : 15 - 30
  • [3] Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy
    Stuart M. Lichtman
    Manpreet K. Boparai
    Current Treatment Options in Oncology, 2008, 9 : 191 - 203
  • [4] Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy
    Lichtman, Stuart M.
    Boparai, Manpreet K.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (2-3) : 191 - 203
  • [5] AN EVALUATION OF POLYPHARMACY AND ADVERSE DRUG EVENTS IN OLDER ADULTS WITH RHEUMATIC DISEASE
    Mooney, Niamh
    Hannon, Evelyn
    Buckley, Mary
    Murphy, Grainne
    AGE AND AGEING, 2019, 48
  • [6] The “iatrogenic triad”: polypharmacy, drug–drug interactions, and potentially inappropriate medications in older adults
    Priscila Horta Novaes
    Danielle Teles da Cruz
    Alessandra Lamas Granero Lucchetti
    Isabel Cristina Gonçalves Leite
    Giancarlo Lucchetti
    International Journal of Clinical Pharmacy, 2017, 39 : 818 - 825
  • [7] Mild polypharmacy and MCI progression in older adults: the mediation effect of drug–drug interactions
    Caterina Trevisan
    Federica Limongi
    Paola Siviero
    Marianna Noale
    Andrea Cignarella
    Enzo Manzato
    Giuseppe Sergi
    Stefania Maggi
    Aging Clinical and Experimental Research, 2021, 33 : 49 - 56
  • [8] Drug therapy for osteoporosis in older adults
    Reid, Ian R.
    Billington, Emma O.
    LANCET, 2022, 399 (10329): : 1080 - 1092
  • [9] Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review
    Soares Rodrigues, Maria Cristina
    de Oliveira, Cesar
    REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2016, 24
  • [10] The "iatrogenic triad": polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults
    Novaes, Priscila Horta
    da Cruz, Danielle Teles
    Lucchetti, Alessandra Lamas Granero
    Leite, Isabel Cristina Gonalves
    Lucchetti, Giancarlo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (04) : 818 - 825